ArticleBone marrow transplantation2014
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.
Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05558319 (GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.Haematologica · 2015Trial
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression - An interdisciplinary prospective study in patients with multiple myeloma.Journal of bone oncology · 2025Article
- Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.HemaSphere · 2024Article
- Outcomes after biochemical or clinical progression in patients with multiple myeloma.Blood advances · 2023Article
- Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.Blood advances · 2021Article
- c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.European journal of haematology · 2020Article
- Review
- Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma.Current hematologic malignancy reports · 2019Review
- Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.Diagnostic pathology · 2018Article
- Multiple Extramedullary Plasmacytoma in a Setting of Complete Bone Marrow Remission: Food for Thought.International journal of hematology-oncology and stem cell research · 2017Article
- Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.Haematologica · 2017Article
- Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.Bone marrow transplantation · 2017Article
- Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.Bone marrow transplantation · 2016Article
- Treatment of relapsed and refractory multiple myeloma.Haematologica · 2016Review
- European perspective on multiple myeloma treatment strategies in 2014.The oncologist · 2014Review
- The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Blood cancer journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The achievement of CR is the crucial step for a prolonged PFS and OS after an autologous SCT in multiple myeloma (MM). Unfortunately, even with the use of new regimens and the current high CR rates, most, if not all, patients will ultimately relapse or progress. We analyzed the type of relapse or progression (asymptomatic vs symptomatic), clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at our institution. After autologous SCT, serological or asymptomatic relapse/progression was observed in about one half of the patients. The treatment-free interval was significantly longer in patients relapsing from CR than in those progressing from PR (P=0.017). Patients with serological relapse/progression had a significantly longer OS than those relapsing from symptomatic disease (P=0.002). The relapse pattern was similar to the initial clinical presentation. Survival after relapse/progression was shorter in those patients with a 24-h urine M-protein excretion of at least 200 mg (P=0.048). Extramedullary involvement was frequent (24%), being the highest risk in patients with extramedullary involvement at diagnosis (P=0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.